Drug Trial Radar · NCT02318329
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Nov 2014
Primary completion
Feb 28, 2019
Study completion Jun 30, 2019
Sponsor
- Lead sponsor
- Five Prime Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
Conditions
- Advanced Solid Tumors
- Gastric Cancer
- Transitional Cell Carcinoma of the Bladder
Interventions
FPA144Drug
FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only).Time frame: 4 weeks on average
- Number of Participants With AEs and Clinical Laboratory Abnormalities (Parts 1B and 2 Only)Time frame: 16 weeks on average
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCSF Helen Diller Family Comprehensive Cancer Center, Mission Bay
San Francisco, California
Innovative Cancer Research Institute
Whittier, California
The University of Chicago Medical Center
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Weill Cornell Medical Center
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Research Institute, LLC
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, South Korea
SMG-SNU Boramae Medical Center
Seoul, South Korea
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
China Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.